Showing 3051-3060 of 6035 results for "".
- Prevent Blindness Provides Free Eye Health Curriculum to Educators to Help Children Learn About Importance of Eye Carehttps://modernod.com/news/prevent-blindness-provides-free-eye-health-curriculum-to-educators-to-help-children-learn-about-importance-of-eye-care/2477518/Schools and educational facilities across the country are now closed due to the COVID-19 pandemic. Many educators, public health and non-profit groups are looking for quality, no-cost educational materials to support remote learning for children. Prevent Blindness is offering the
- Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19https://modernod.com/news/johnson-johnson-announces-a-lead-vaccine-candidate-for-covid-19/2477489/Johnson & Johnson announced a $1 billion deal with the U.S. government to create enough manufacturing capacity to make more than 1 billion doses of a potential vaccine for COVID-19. Johnson & Johnson said on Monday it has been working on a vaccine since January 2020 and expects to initiat
- Nano Retina Announces Preliminary Results for First-in-Human Implantation of Its NR600 Artificial Retina Devicehttps://modernod.com/news/nano-retina-announces-preliminary-results-for-first-in-human-implantation-of-its-nr600-artificial-retina-device/2477482/Nano Retina, developer of the NR600, an artificial retina device that mimics the natural physiological processes of the human eye and restores functional vision to persons blinded by retinal degenerative diseases, reported preliminary results for first-in-human implantations of its artificial ret
- Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minuteshttps://modernod.com/news/abbott-launches-molecular-point-of-care-test-to-detect-novel-coronavirus-in-as-little-as-five-minutes/2477479/Abbott announced that the FDA has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as 5 minutes and negative results in 13 minutes, according to a company new
- FDA Grants Gilead Request to Drop Orphan Drug Designation for Potential COVID-19 Treatment Remdesivirhttps://modernod.com/news/fda-grants-gilead-request-to-drop-orphan-drug-designation-for-potential-covid-19-treatment-remdesivir/2477465/The FDA on Wednesday withdrew an orphan drug designation it had granted Gilead Sciences a few days ago for its investigational antiviral remdesivir to treat COVID-19. The company, which had made the request, said it will waive all benefits that come with the designation, including an
- ASCRS to Host Webinars for Eye Care Professionals Dealing With COVID-19 Outbreakhttps://modernod.com/news/ascrs-to-host-webinars-for-eye-care-professionals-dealing-with-covid-19-outbreak/2477450/The American Society of Cataract and Refractive Surgery (ASCRS) will host two webinars this week for ophthalmologists and eye care professionals to help deal with the manifestations of COVID-19. On Wednesday, March 25, ASCRS will host a complimentary webinar on “Neurotrophic Keratiti
- Adaptive Biotechnologies and Microsoft Expand Partnership to Decode COVID-19 Immune Response and Provide Open Data Accesshttps://modernod.com/news/adaptive-biotechnologies-and-microsoft-expand-partnership-to-decode-covid-19-immune-response-and-provide-open-data-access/2477435/Adaptive Biotechnologies and Microsoft announced they will leverage their existing partnership mapping population-wide adaptive immune responses to diseases at scale to study COVID-19. Finding the relevant immune response signature may advance solutions to diagnose, treat and prevent the disease,
- Lenstec Submits Premarket Approval Application to FDA for SBL-3 IOLhttps://modernod.com/news/lenstec-submits-premarket-approval-application-to-fda-for-sbl3-iol/2477408/Lenstec has announced its has submitted a premarket approval (PMA) application to the FDA for the SBL-3 IOL. The Lenstec SBL-3 (segmented bifocal lens) is an asymmetric multifocal refractive IOL utilizing a 3-diopter add with a transition zone connecting the distanc
- Eli Lilly Joins Race to Develop Coronavirus Treatmenthttps://modernod.com/news/eli-lilly-joins-race-to-develop-coronavirus-treatment/2477398/Pharmaceutical giant Eli Lilly & Co. has entered an agreement to develop an experimental therapy for the new coronavirus with with closely held biotechnology company AbCellera Biologics Inc., according to a Bloomberg
- Second Sight Announces Departure of Will McGuire, President and CEO, and Appointment of Gregg Williams as Acting CEOhttps://modernod.com/news/second-sight-announces-departure-of-will-mcguire-president-and-ceo-and-appointment-of-gregg-williams-as-acting-ceo/2477384/Second Sight Medical Products announced the departure of Will McGuire, President and Chief Executive Officer, effective March 27, 2020, to pursue another professional opportunity located closer to his family. Mr. McGuire remains as a director on Second Sight’s board. Effective March 27, 20